ClinicalTrials.gg
CompletedNCT05981040Updated Dec 19, 2024

Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

A Phase 2 interventional study of ZYIL1 capsules 25 mg and 50 mg Placebo and ZYIL1 capsules 50 mg and 25 mg Placebo in Amyotrophic Lateral Sclerosis, sponsored by Zydus Lifesciences Limited. Completed at 7 sites in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Zydus Lifesciences Limited · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

ZYIL1 is expected to show benefit in patients with Amyotrophic Lateral Sclerosis (ALS). The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with ALS.

Read the detailed description

This is a proof-of-concept, placebo controlled, randomized, multi-centre,double blind study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with Amyotrophic Lateral Sclerosis following a twice daily oral administration of ZYIL1 or matching placebo to patients aged between 18 and 80 years (inclusive at screening).

Treatment duration will be twelve (12) weeks.

02

Conditions studied

  • Amyotrophic Lateral Sclerosis
03

In context

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

This study's enrollment of 24 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.

Browse Amyotrophic Lateral Sclerosis studies →

Lead sponsor

Zydus Lifesciences Limited is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and/or female patients aged between 18 and 80 years (inclusive at screening).
  2. Diagnosis of probable or definite ALS, according to the revised version of the El Escorial World Federation of Neurology criteria. Refer Appendix III - El Escorial Criteria.
  3. Time since onset of first symptom of ALS ≤9 months
  4. Slow Vital Capacity (SVC) ≥ 50% of the predicted value
  5. Be able to swallow the study capsules during study
  6. Either not currently receiving riluzole or on a stable dose of riluzole for at least 4 weeks before the screening visit. Participants receiving riluzole are expected to remain on the same dose throughout the duration of the study
  7. Either not currently receiving edaravone or on edaravone treatment. Participants receiving edaravone must have completed at least 1 cycle of treatment before the screening visit and are expected to continue with stable dose edaravone treatment throughout the duration of the study.
  8. Female patients must be non-pregnant, non-lactating and women of / sexually active women, unless surgically sterile (at least 6 months prior to study drug administration) or * for at least 12 consecutive months, must agree to use adequate (hormonal contraceptives [combined estrogen and progestogen oral contraceptive, patch, contraceptive vaginal ring, injectable progestogen, and implants] or contraceptive subdermal implant or percutaneous contraceptive patches or intrauterine device [IUD] or intrauterine system [IUS]; vasectomy and tubal ligation or barrier method of birth control; female condom with spermicide, cervical cap, diaphragm with spermicide, contraceptive sponge), absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to study drug administration], during study and up to 32 days after the last dose of study drug.

    *Postmenopausal defined as 12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g., age appropriate, >45 years, in the absence of hormone replacement therapy).

  9. All male patients should avoid fathering a child by either true abstinence, hormonal or barrier method (e.g., male condom with diaphragm, male condom with cervical cap) or with their sexual partner the use of effective means of contraception throughout and till 92 days of administration of the last dose. They must not donate sperm for at least 92 days after the last dose of study drug.
  10. Ability to provide written and to be compliant with the schedule of protocol assessments. In case of illiterate patients, thumb impression of the patients will be obtained along with the signature of the impartial witness or legally authorized representative (LAR) on the consent form prior to patient's participation in the trial.Date of ALS Symptom Onset. For the purposes of this study, the date of symptom onset will be defined as the date the subject first had symptoms of their disease, i.e., weakness. To be eligible for this study, the date of symptom onset must be no greater than exactly 9 months prior to the Screening Visit date.

Exclusion criteria

Exclusion Criteria:

  1. With significant cognitive impairment, psychiatric disease, other neurodegenerative disorder (e.g., Parkinson disease or AD), substance abuse other causes of neuromuscular weakness, or any other condition that would make the participants unsuitable for participating in the study or could interfere with assessment or completing the study in the opinion of the Investigator.
  2. History of recent serious infection (e.g., pneumonia, septicemia) within 4 weeks of the screening visit; infection requiring hospitalization or treatment with IV antibiotics, antivirals, or antifungals within 4 weeks of screening; or chronic bacterial infection (such as tuberculosis) deemed unacceptable as per the Investigator's judgment
  3. With active herpes zoster infection within 2 months prior to the screening visit
  4. A documented history of attempted suicide within 6 months prior to the screening visit, or in the Investigator's judgment are at risk for a suicide attempt
  5. History of unstable or severe cardiac, pulmonary, oncological, hepatic, or renal disease or another medically significant illness other than ALS precluding their safe participation in this study
  6. Participants who are pregnant or are currently breastfeeding
  7. A known history of allergy to any ingredients of ZYIL1
  8. Patients taking concomitant medicines within 7 days or 5 half-lives of the medication (whichever is longer) prior to first dose of study drug administration till end of the study, which are substrate of CYP1A2 enzymes (e.g., alosetron, caffeine, duloxetine, melatonin, ramelteon, tasimelteon, tizanidine etc.) and CYP2B6 enzymes (e.g., bupropion, efavirenz etc.).
  9. Use of any , colchicine or anti-IL-1 inhibitors within 7 days or 5 half-lives of the medication (whichever is longer) prior to first dose of study drug administration.
  10. Use of any drugs concurrently or within 4 weeks or 5 half-lives (whichever is longer), prior to first dose of study drug administration.
  11. Any and/or laboratory significant value or other instability that would prevent the patient from participating in the study as determined by the Investigator.
  12. Received a within 14 days before the screening visit or planning to receive during the study
  13. Participants who have received stem cell or gene therapy for ALS at any time in the past
  14. Any of the following laboratory values at screening

    • (ALT) or aspartate aminotransferase (AST) >3.0 × (ULN)
    • >1.5 × ULN unless the participant has documented Gilbert syndrome (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%)
    • Estimated \<60 mL/min/1.73 m2 (Modification of Diet in Renal Disease [MDRD])
  15. corrected for heart rate using Fridericia's method (QTcF) > 450 msec at screening.
  16. to lumbar puncture including but not limited to lumbar scoliosis, coagulopathy, infection at site of puncture, use of anticoagulants at the time of study enrolment.
  17. Participant with seizure disorder or history of seizures within 6 months.
  18. Surgery within last 3 months or planned major surgery within next 3 months from the date of screening (other than minor cosmetic surgery and minor dental surgery).
  19. Use or intended use of any medications/products known to alter drug absorption, metabolism, or elimination processes including St John's Wort within 4 weeks prior to receiving study drug and up to end of study. Use of such medication will be considered on a case-by-case basis as per the opinion of the Investigator and/or independent medical monitor.
  20. Use of grapefruit or similar substances (Seville oranges or marmalade, grapefruit juice, grapefruit hybrids, pomelos, exotic citrus fruits or fruit juices) within 7 days prior to first dose of study drug until last dose administration.
  21. Donation of blood or blood products within 3 months prior to screening.
  22. History of, or positive screening test for, infection (defined as positive for hepatitis C virus antibody), infection (defined as positive for hepatitis B surface antigen), or I or II.
  23. Use or intended use of any over-the-counter (vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) or prescription medications within 7 days or 5 half-lives (whichever is longer) prior to receiving study drug, with the exception of hormone replacement therapy and therapies for chronic stable diseases that have been stable for at least 30 days prior to screening and until Day 1, unless deemed acceptable by the Investigator.
  24. Inability to be venipunctured or tolerate venous puncture.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Arm 1

    ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule

    Drug: ZYIL1 capsules 25 mg and 50 mg Placebo

  • Active comparator
    Arm 2

    ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule

    Drug: ZYIL1 capsules 50 mg and 25 mg Placebo

  • Active comparator
    Arm 3

    ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration

    Drug: ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg

  • Placebo comparator
    Arm 4

    Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule

    Drug: Matching placebo 25 mg and Matching placebo 50 mg

Interventions

  • DrugZYIL1 capsules 25 mg and 50 mg Placebo

    ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule

  • DrugZYIL1 capsules 50 mg and 25 mg Placebo

    ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule

  • DrugZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg

    Drug page: ZYIL1Studies of ZYIL1ZYIL1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration

  • DrugMatching placebo 25 mg and Matching placebo 50 mg

    Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule

06

What researchers measure

Primary outcomes

  1. Change from baseline in the ALSFRS-R total score

    Time frame: From baseline to Week 12

Secondary outcomes

  1. Time from baseline to the occurrence of either death, or permanent assisted ventilation

    Time frame: Baseline to Week 12 (>22 hours daily for >7 consecutive days), whichever comes first )

  2. Change from baseline in slow vital capacity (SVC)

    Time frame: Baseline to Week 12

  3. Change from baseline in serum neurofilament light chain biomarker

    Time frame: Baseline to Week 12

  4. Number of patients with treatment emergent adverse events

    Time frame: Baseline to Week 12

  5. Number of patients with Serious adverse event (SAE)

    Time frame: Baseline to Week 12

  6. Cmax

    Time frame: baseline to Week 12

  7. AUC

    Time frame: baseline to Week 12

  8. Tmax

    Time frame: baseline to Week 12

07

Study locations

7 sites
  • Zydus Hospitals & Healthcare Research
    Ahmedabad, Gujarat, India
  • Rhythm heart institute
    Vadodara, Gujarat, India
  • BrainS Super Speciality Hospital
    Bengaluru, Karnataka, India
  • KIMS-Kingsway Hospitals
    Nagpur, Maharashtra, India
  • Surya Multispecialty Hospital
    Nashik, Maharashtra 422003, India
  • CIMET's Inamdar Multispeciality Hospital
    Pune, Maharashtra, India
  • Sir Ganga Ram Hospital
    New Delhi, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jun 2024, 7 months.

Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 7 months is below that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Aug 8, 2023
StartActual
Nov 9, 2023
Primary completionActual
Jun 26, 2024
CompletionActual
Jun 26, 2024
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05981040
Responsible party
Sponsor
First posted
Aug 8, 2023
Start date
Nov 9, 2023
Primary completion
Jun 26, 2024
Completion
Jun 26, 2024
Last update
Dec 19, 2024

Study contacts

Dr. Deven Parmar, MD,FCP
study chair · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZYIL1

Start the discussion